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Abstract: The cerebral vasospasm is still considered the most devastating complication 
for the patients with aneurysmal subarachnoid haemorrhage. The aim of this study was 
to evaluate the efficiency of intra-arterial nimodipine administration in cerebral 
vasospasm diminutions and outcome of the patients.  
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Introduction 
Cerebral ischemia due to severe vasospasm 
is the major factor of secondary morbidity and 
mortality for the patient with aneurysmal 
subarachnoid hemorrhage. The medical 
management of this clinical situation has been 
improved over the last decades and the current 
strategies for preventing vasospasm comprise 
both medical and interventional measures. 
Thus, the use of intraoperative intracisternal 
thrombolysis or intracisternal application of 
nicardipine-prolonged implants followed by 
oral nimodipine administration and 
hemodynamic therapy demonstrates 
effectiveness in preventing cerebral 
vasospasm. Even with these therapeutic 
methods, the level of permanent disabilities 
due to cerebral vasospasm is still significant 
(10% - 20%) [1, 3, 4]. This situation led to 
development of alternative endovascular 
strategies such as balloon angioplasty and 
intra-arterial spasmolysis with nimodipine or 
papaverine.  
The objective of our study was to 
investigate the effect of intra-arterial 
nimodipine administration to the patient with 
aneurysmal subarachnoid hemorrhage treated 
in our clinic.  
Material and methods 
51 patients with aneurysmal subarachnoid 
hemorrhage were endovascular treated for 54 
aneurysm at our institution between 
September 2015 and September 2016. From 
this group of patients 10 cases underwent 
intra-arterial injection of nimodipine for the 
treatment of subarachnoid hemorrhage 
induced vasospasm. 7 patients received intra-
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arterial nimodipine injection immediately 
before and after the procedure of aneurysm 
occlusion with coils. These were due to the 
delayed addressing to our clinic (day 5 to day 
9 after rupture) in which the cerebral 
vasospasm was imaging and clinical 
manifested. The other 3 patients benefit of 
intra-arterial nimodipine injection a few days 
after the procedure of aneurysm coils 
occlusion for cerebral vasospasm highlighted 
on echo Doppler monitoring and clinically 
manifested. 
The following protocol is discussed to be 
used at our institution for the management of 
sever cerebral vasospasm after aneurysmal 
subarachnoid hemorrhage. After the 
procedure of aneurysm occlusion, continuous 
monitoring of intracranial flow velocities 
detected by transcarnial Doppler (TCD) is 
started daily in at least two arterial segments 
on both parts. For asymptomatic patients with 
TCD flow acceleration above 120 cm/s, a 
moderate hypertensive and hypervolemic 
therapy is applied along with continuing to use 
the oral administration of 60 mg of 
nimodipine doses every 4 hours. When 
vasospasm is suspected clinically (conscious 
patient with transient neurological deficits or 
confused patient), a brain computer 
tomography is performed to confirm the 
presence or absence of ischemia. The patient is 
then transferred to the Intensive Care Unit and 
a maximal triple H therapy is administrated. If 
the patient's clinical status continues to worsen 
and the intracranial flow velocities as detected 
by TCD exceeds 150 cm/s, a endovascular 
intra-arterial nimodipine injection is taken in 
to discussion to be initiated. A catheter it will 
be placed within internal carotid artery 
(segment C3-C2) and a bolus of 1mg (5ml 
nimodipine and 15ml saline) will be 
administrated in a time of 5 minutes. The 
follow-up angiography will be performed after 
10 minutes. If only minor angiographic effects 
are visualized a second bolus injection is 
performed. For the next 7 days a treatment 
with 1 mg of nimodipine, i.e. 5 ml Nimotop 
solution, (about 15 μg/kg bw/h), should be 
infused each hour via a central catheter. 
Patients of body weight less than 70 kg or with 
unstable blood pressure should be started on a 
dose of 0.5 mg nimodipine per hour (2.5 ml of 
Nimotop solution), or less if necessary. If the 
neurological status it will stabilize in this 
period of time a change to Nimotop tablets 
could be initiated and the total duration of 
treatment should not exceed 21 days.  
We retrospectively reviewed clinical dates 
and imaging reports (angiography and CT) of 
these 10 patients who received intra-arterial 
nimodipine administration. The endovascular 
angiography and procedure were performed 
using a 5F or 4F diagnostic catheter placed in 
the internal carotid artery. Nimodipine was 
administrated in a solution of NaCl 9% (5ml 
nimodipine and 15ml NaC 9%). The dose 
varied from 1mg to 3 mg per vessel. Blood 
pressure and heart rate were continuously 
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monitored as parameters for systemic side-
effect. Repeat angiography control exposures 
were performed at 10 minutes after each 
session of nimodipine administration. The 
frontal angiography projections on arterial 
phase were compared with focalization on A1 
and M1 segments. The post endovascular 
procedure clinical examinations were 
determined as improved, stable or worse. 
Cerebral CT scan acquisitions before and after 
treatment were confronted to identify same 
particular signs as edema, infarction, 
hydrocephalus or a new hemorrhage.  
Results 
Of the 51 patients with ruptured aneurysm 
treated by endovascular coil occlusion 10 
patient received intra-arterial nimodipine 
administration. The mean age of patients was 
53.4 (interval range, 36 to 74 years). The sex 
(male and female) ratio was equal. 5 patients 
had Hunt&Hess grade III, 2 had grade II, one 
had grade IV and 2 had grade I. The average 
dose of nimodipine per patient was 2 + 0.5mg.  
Only two patients received two separate 
treatments. Nine injection procedures were 
performed under general anesthesia and three 
only with local one. Notable angiographic 
vascular dilatation was identified in 9 of the 12 
procedures and in 8 patients. The comparative 
analysis of brain CT scans pre and post-
procedural showed ischemic changes in 2 
patients. Administration of intra-arterial 
nimodipine had insignificant systemic effects. 
In two patients the systolic blood pressure 
dropped with 30 mmHg. There was no severe 
bradycardia or significant elevation of 
intracranial pressure (Table 1).  
Clinical evolution after the endovascular 
chemical treatment was improved in 6 patients 
(GOS 5), stable in two (GOS 3) and worse in 
one (GOS 4). One patient died at 3 days after 
second session of intra-arterial nimodipine 
administration (GOS 1) due to an 
uncontrollably severe vasospasm that caused 
extensive hemispheric ischemia.  
Illustrative cases  
A 48 year-old female presented to our 
clinic with confusion and severe headache 
syndrome. The family declared the onset of 
symptoms after seven days. Brain CT at 
admission revealed a slight subarachnoid 
haemorrhage in left sylvian fissure. 
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Figure 1 - A - Diagnostic brain CT revealing a slight 
subarachnoid haemorrhage in left sylvian fissure; B - 
CTA showing a voluminous left internal carotid 
artery aneurysm (ophthalmic segment); C - DSA  
showing sever diffuse cerebral vasospasm; D – DSA 
after IAN showing good diminishes of vasospasm; E 
– DSA control after aneurysm embolization and 
second IAN administration; F - Brain CT 
postembolization 
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Table I 
Patients’ characteristics 
 
Discussion 
The clinical effects of the endovascular 
methods used to treat symptomatic vasospasm 
after aneurysmal subarachnoid haemorrhage 
were investigated by many studies. Intra-
arterial nimodipine injection and balloon 
angioplasty are widely accepted as rescue 
therapies in most of neurosurgical Units when 
maximized medical therapy fails. The balloon 
angioplasty is well known as the most effective 
endovascular procedure due to nearly 
permanent reversal of vasospasm. This 
procedure is limited to proximal vessel 
segments and may be accompanied by a series 
of complications. The most serious 
complications are vessel occlusion or rupture 
and coils or clip displacement. Because this 
procedure can be accompanied by several 
technical difficulties it should be performed in 
centers with experienced endovascular 
surgeons [1, 2, 4].  
Intra-arterial administration of 
vasodilatators has been demonstrated a good 
alternative to mechanical angioplasty with 
optimal results in reversing angiographic 
vasospasm and in reducing flow velocities 
detected by TCD. The literature studies have 
reported using nimodipine, nicardipine or 
verapamil as calcium channel blockers for 
intra-arterial treatment of cerebral vasospasm. 
Biondi et al reported a 76% of clinical 
improvement, 63% notable angiographic 
vessel dilation after intra-arterial nimodipine 
administration and 72% of patients with 
favourable outcome. Hanggi and all reported 
also 63% patients with significant vascular 
dilatation with a 93% clinical improvement 
after the procedure [2, 5, 6].  
The clear efficiency of IAN is still 
questionable. Most of the investigations 
showed that nimodipine is effective in 
diminishing vasospasm in case where 
intensive medical therapy fails, the therapy 
could be done in the same session with 
aneurysm coil occlusion, the procedure is 
temporary and may need repeated sessions, 
and the administration is more efficient in 
dilating small branches than large one [4, 7, 8].  
Patient 
No  
Age / 
Sex  
H&H 
Grade 
Fisher 
Grade 
Aneurysm 
Location 
Day of  
Surgery 
Day of IAN 
administration 
Dose of IAN/ 
Session  
GOS 
1 54/F II 2 AcoA 0 9 1 5 
2 42/M III 3 AcoA  8 8 2 3 
3 62/F IV 4 MCA 6 6, 8 4 1 
4 48/F III 2 ACI oft 7 7 1.5 5 
5 53/M III 4 AcoA 3 5 1.5 5 
6 49/F I 1 MCA 5 5 1 5 
7 74/M III 3 PcoA 1 12, 13 4 4 
8 55/M I 2 AcoA 2 10 2 5 
9 36/M II 2 MCA 4 8 2 5 
10 61/F III 4 PcoA 9 9 1 3 
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Conclusion 
Our study is by some factors like number 
of cases and additional monitoring 
investigations (perfusion parameters: MTT – 
mean transit time,  Tmax – selective time to 
peak of the brain parenchyma, rCBV – 
regional cerebral blood volume, rCBF – 
regional cerebral blood flow) [3]. The results 
of our retrospective analysis suggest that IAN 
is effective and safe in selected cases of 
vasospasm following aneurysmal SAH. We 
consider that a prospective and mare large 
randomized study is needed to confirm these 
results. 
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